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Abstract
Background
The prognosis of intrahepatic cholangiocarcinoma (ICC) has been poor, because of the high
recurrence rate even after curative surgery. This study aimed to evaluate the prognostic
impact of surgical resection of recurrent ICC.
Patients and methods
A total of 345 cases of ICC who underwent hepatectomy with curative intent in 17 institutions
were retrospectively analyzed, focusing on recurrence patterns and treatment modalities for
recurrent ICC.
Results
Median survival time and overall 5-year recurrence-free survival rate were 17.8 months and
28.5%, respectively. Recurrences (n = 223) were classified as early (recurrence at�1 year,
n = 131) or late (recurrence at >1 year, n = 92). Median survival time was poorer for early
recurrence (16.3 months) than for late recurrence (47.7 months, p<0.0001). Treatment
modalities for recurrence comprised surgical resection (n = 28), non-surgical treatment (n =
134), and best supportive care (BSC) (n = 61). Median and overall 1-/5-year survival rates
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after recurrence were 39.5 months and 84.6%/36.3% for surgical resection, 14.3 months
and 62.5%/2.9% for non-surgical treatment, and 3 months and 4.8%/0% for BSC, respec-
tively (p<0.0001). Multivariate analysis identified early recurrence, simultaneous intra-
and extrahepatic recurrence, and surgical resection of recurrence as significant prognostic
factors. In subgroup analyses, surgical resection may have positive prognostic impacts
on intra- and extrahepatic recurrences, and even on early recurrence. However, simulta-
neous intra- and extrahepatic recurrence may not see any survival benefit from surgical
management.
Conclusion
Surgical resection of recurrent ICC could improve survival after recurrence, especially for
patients with intra- or extrahepatic recurrence as resectable oligo-metastases.
Introduction
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary malignant
tumor of the liver, accounting for 10–20% of all primary liver malignancies [1]. Surgery has
been regarded as a potentially curative treatment, providing ICC patients with a median over-
all survival (OS) of 14.4–38.8 months [2–4]. Unfortunately, many cases are diagnosed at an
advanced stage, because ICC shows few specific early symptoms. Only about 20–40% of poten-
tially operable patients are offered operative resection [5]. On the other hand, several reports
have described the efficacy of systemic chemotherapy. While various regimens can achieve
partial response, the effects seem limited [6–8].
Recurrence after curative surgery for ICC is common, with a reported recurrence rate of
50–79% [2, 4, 9, 10]. Many and various clinical factors have been identified as risk factors for
recurrence and poor survival [11–15]. As with hepatocellular carcinoma (HCC), ICC shows
a metastatic predilection for the liver, so locoregional therapy may represent a reasonable
approach [16]. Ercolani et al. reported that aggressive multimodal treatment of recurrent ICC
is associated with better outcomes [15]. A multi-institutional study showed that re-resection
contributed to relatively better prognosis than systemic chemotherapy or best supportive
care (BSC) [10]. A steadily improving understanding of risk factors for ICC recurrence and
improved postoperative monitoring with modern imaging modalities is increasingly permit-
ting diagnosis of recurrent ICC at an early stage while repeat resection is still technically feasi-
ble [5]. Considering these circumstances, re-evaluation of the efficacy of surgery for ICC
recurrence appears worthwhile.
The aim of this study was to evaluate the prognostic impact of surgical resection for recur-
rent ICC, with a particular focus on the timing and patterns of recurrence.
Materials and methods
Study subjects
Participants in the present multicenter, retrospective comprised 404 adult subjects who had
undergone hepatic resection with curative intent between January 2000 and December 2016.
Clinical data for these subjects were collected from 17 medical institutions (Okayama Uni-
versity Hospital, Okayama Saiseikai General Hospital, Hiroshima Citizens Hospital, Kochi
Health Sciences Center, Himeji Red Cross Hospital, National Fukuyama Medical Center,
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Tottori Municipal Hospital, Tenwakai Matsuda Hospital, National Okayama Medical Cen-
ter, Fukuyama City Hospital, Himeji St. Maria Hospital, Matsuyama Municipal Hospital,
Sumitomo Besshi Hospital, Onomichi Municipal Hospital, National Iwakuni Medical Cen-
ter, Himeji Central Hospital, and Kobe Red Cross Hospital). Of these, 12 institutions are
board-certified training institutions for the Hepatobiliary and Pancreatic Surgery program
in Japan [17]. Consequently, most patients were recruited from high-volume centers, leading
to relatively standardized operative procedures and outcomes. Subjects meeting any of the
following criteria were excluded: 1) insufficient clinical records (n = 35); 2) surgery-related
death (n = 17); or 3) lack of follow-up data (n = 7). The definition of surgery-related death
was mortality due to surgical complications within 90 days after surgery. On the other hand,
comparatively early deaths due to recurrent tumor progression were not excluded. After
excluding those individuals who met the exclusion criteria, a total of 345 subjects were
included in this study.
The following demographic and clinical data were reviewed through medical records: age;
sex; body mass index (BMI); history of diabetes mellitus; serum levels of carbohydrate antigen
(CA)19-9 and carcinoembryonic antigen (CEA); maximum tumor diameter; number, localiza-
tion, and morphology of tumors; surgical procedure; histological grade; vascular/serosal inva-
sion; and timing and patterns of recurrence. With regard to localization of primary ICC, all
ICCs were classified as hilar or peripheral type based on the anatomical origin of the tumor.
The anatomical location of the tumor was judged from preoperative imaging such as com-
puted tomography (CT) or magnetic resonance imaging (MRI). Tumors with the intrahepatic
component and involvement of a large bile duct comparable with the intrahepatic second or
third branches were defined as hilar type, whereas the other tumors involved in smaller than
segmental branches were defined as peripheral type ICC.
Follow-up protocol and diagnosis of recurrence
Patients with lymph node metastasis and/or positive surgical margins received adjuvant
chemotherapy with regimens comprising gemcitabine and cisplatin or oral fluorinated
pyrimidine for 6 months. After initial surgery, all patients were regularly followed-up every
3 months for the first 2 years, and every 6 months thereafter. At each visit, in addition to
basic blood examinations, serum CA19-9 and CEA levels, contrast-enhanced chest and
abdominal CT, and/or abdominal MRI were examined. Positron emission tomography
(PET) was added in patients showing suspected subclinical recurrence or extrahepatic
metastasis on CT or MRI. Diagnosis of recurrence was mainly based on these radiological
findings with or without elevated concentrations of CA19-9. For cases without these defini-
tive findings, diagnosis required endoscopic or percutaneous biopsy. Recurrence at�1 year
postoperatively was defined as early recurrence, as reported previously [18]. Recurrence at
>1 year was thus defined as late recurrence.
Treatment modalities for recurrence and decision of them
Treatment strategy for each case of recurrence was assessed by a multidisciplinary team com-
prising liver surgeons, oncologists, hepatologists, and radiologists. Surgical resection for the
recurrent site could be indicated, according to technical resectability, such as solitary or oligo-
metastasis and patient conditions including performance status, estimated volume of future
liver remnant, and feasibility and tolerability of repeat surgery. Of course, complete resection
as R0 was required as the intent of repeat surgery. Patients who did not meet these criteria
were treated by chemotherapy and/or radiation therapy as non-surgical treatment, or by BSC.
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Statistical analysis
Clinical variables were compared using the Mann-Whitney U test for continuous data and the
Pearson’s correlation coefficient for categorical data. Continuous variables are presented as
median and interquartile range (IQR). Values of p<0.05 were considered significant. OS
was evaluated using the Kaplan-Meier method and compared using log-rank testing. Cox’s
proportional hazard model was used to identify prognostic factors for recurrent cases. For this
analysis, clinical variables showing values of p<0.10 in univariate analyses were entered into
multivariate analysis. Hazard ratios (HRs) and 95% confidence intervals (95%CIs) were calcu-
lated. All statistical analyses were performed using JMP version 14 (SAS Institute Inc., Cary,
NC, USA)).
Ethics statement
This study conformed to the Declaration of Helsinki on Human Research Ethics standards
and was approved by the Okayama University Hospital Institutional Ethics Board (number
1701–026). Since this study was retrospective in nature, there was no written informed consent
from the investigated patients. All data were blinded before analysis.
Results
Demographic characteristics of patients are provided in Table 1, and patient flow is summa-
rized in Fig 1. The predominant tumor morphology was the mass-forming type (n = 256), fol-
lowed by the periductal infiltrating type (n = 77), and intraductal growth type (n = 12). With
regard to surgical procedures, more than 70% of patients underwent right/left hemi-hepatec-
tomy or trisectionectomy as major hepatectomy, due to tumor extension. Most patients with
tumor adjacent to the biliary confluence, such as hilar-type ICC, underwent bile duct resec-
tion. In our cohort, therapeutic lymph node dissection (LND) was performed for 235 patients
(68%), of whom 96 patients showed positive lymph node metastasis on final histopathological
examination; the rate of lymph node metastasis was 41%. The rate of positive surgical margins
(including bile duct or liver cut surface) was 16%. Patients showing lymph node metastasis
and/or positive surgical margins received adjuvant chemotherapy for 6 months.
A total of 223 patients showed recurrent ICC, with a median recurrence-free survival (RFS)
of 17.8 months. Univariate analysis indicated the following significant risk factors for recur-
rence: preoperative CA19-9; maximum tumor diameter; periductal infiltrating type as the
morphological type; multiple nodules; hilar-type ICC; requirement of major hepatectomy;
LND; bile duct resection; vascular reconstruction; adjuvant chemotherapy; positive results for
microscopic surgical margins; serosal invasion; positive lymph nodes; vascular invasion; and
poorly/undifferentiated tumor (Table 1).
Patients with recurrence were divided into two groups according to the time to recurrence
(TTR): early recurrence,�1 year after surgery (n = 131); and late recurrence,>1 year after sur-
gery (n = 92). From other perspectives, pattern of recurrence was classified as intrahepatic
only (n = 79); extrahepatic only (n = 109); or simultaneous intra- and extrahepatic recurrence
(n = 35) (Fig 2a). The most frequent site of extrahepatic metastasis was lung (n = 49), followed
by pleura/peritoneum including local recurrence (n = 42), lymph node (n = 40), bone (n = 11),
and adrenal grand (n = 2) (Fig 2b). Treatment modalities for these recurrences comprised sur-
gical resection (n = 28), non-surgical treatment (n = 134), and BSC (n = 61). Rates of surgical
resection were high for intrahepatic-only recurrence and late recurrence. Surgical resection of
recurrent sites comprised repeat hepatectomy for intrahepatic recurrence (n = 14) and local
recurrence (n = 1), lung resection (n = 6), LND (n = 3), resection of local recurrence with bile
duct (n = 1), adrenectomy (n = 1), and partial resection of abdominal wall (n = 1). On the
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other hand, non-surgical treatment comprised systemic chemotherapy alone (n = 113), radia-
tion (n = 10), chemo-radiation (n = 6), and radiofrequency ablation (n = 5). Clinical back-
grounds of all recurrent cases according to treatment modalities are summarized in Table 2.
In view of higher concentrations of preoperative CA19-9 and rates of lymph node metastasis,
serosal invasion, and requirement of major hepatectomy, initially advanced ICC was signifi-
cantly associated with non-surgical treatment or BSC. On the other hand, the group of patients
who underwent surgical resection showed the highest induction rate of adjuvant chemother-
apy (50%), followed by 48% for patients with non-surgical treatment, and 24% for patients
receiving only BSC (p = 0.006). In terms of timing and pattern of recurrence, early recurrences
were less likely to receive intervention by surgical resection, compared with late recurrence
(p = 0.028). That is, early recurrences were treated using other modalities (p = 0.028) (Fig 3).
Intrahepatic- or extrahepatic-only metastasis in late recurrence could be selected for surgical
resection: resection rates were 31% for intrahepatic recurrence alone, and 13% in extrahepatic
recurrence alone. However, only 10% of simultaneous intra- and extrahepatic recurrences met
the indications for surgical resection (Fig 1).
Table 1.
Variables All (n = 345) Recurrence (n = 223) No Recurrence (n = 122) P-value���
Parameters at initial resection
Sex: Male / Female (%) 214 (62%) / 131 (38%) 138 (62%) / 85 (38%) 76 (62%) / 46 (38%) 0.94
Age � 70 (63–76) 70 (63–76) 69 (64–77) 0.579
BMI � 22 (20–24.8) 22 (19.9–24.5) 22.2 (20.1–25.9) 0.174
Diabetes mellitus (%) 66 (20%) 41 (18%) 25 (21%) 0.634
Tumor factors
CEA (ng/ml) � 2.9 (1.8–5.8) 2.9 (1.8–6.1) 2.8 (1.8–9.9) 0.394
CA19-9 (U/ml) � 39.8 (14.7–212) 56.2 (16–456) 27 (12.6–87.7) 0.004
Maximum tumor diameter (cm) � 4.3 (2.8–6.7) 4.8 (3.1–7) 3.3 (2.4–5) <0.0001
Morphology
Mass forming / Periductal infiltrating / Intraductal growth
(%)
256 (74%) / 77 (22%) / 12
(4%)
164 (74%) / 55 (25%) / 4
(2%)
92 (75%) / 22 (18%) / 8
(7%)
0.035
Solitary / Multiple lesion (%) 275 (80%) / 70 (20%) 166 (74%) / 57 (26%) 109 (89%) / 13 (11%) 0.001
Hilar type / Peripheral type (%) 125 (36%) / 220 (64%) 94 (42%) / 129 (58%) 31 (25%) / 91 (75%) 0.002
Treatment factors
Major hepatectomy / Minor hepatectomy (%) 247 (72%) / 98 (28%) 170 (76%) / 53 (24%) 77 (63%) / 45 (37%) 0.009
Lymph node dissection (%) 235 (68%) 161 (72%) 74 (61%) 0.027
Bile duct resection (%) 100 (29%) 77 (35%) 23 (19%) 0.002
Vascular reconstruction (%) 26 (7.5%) 21 (9%) 5 (4%) 0.073
Adjuvant Chemotherapy (%) 123 (35%) 93 (42%) 30 (25%) 0.002
Pathological factors
Microscopic surgical margin positive (%) 56 (16%) 45 (20%) 11 (9%) 0.007
Lymph node metastasis (%) �� 96 (41%) 79 (48%) 17 (23%) 0.0004
Serosa invasion (%) 139 (40%) 111 (49%) 28 (23%) <0.0001
Vascular invasion (%) 219 (63%) 165 (74%) 54 (44%) <0.0001
fibrosis (%) 90 (26%) 52 (23%) 38 (31%) 0.113
Poorly/undifferentiated (%) 71 (21%) 54 (24%) 17 (14%) 0.023
� Median and IQR: interquartile range,
�� Among cases with lymph node dissection,
��� Recurrence vs No Recurrence.
https://doi.org/10.1371/journal.pone.0238392.t001
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Fig 1. Inclusion and exclusion criteria applied in the present study.
https://doi.org/10.1371/journal.pone.0238392.g001
Fig 2. Recurrent pattern (a) and sites of extrahepatic recurrence (b).
https://doi.org/10.1371/journal.pone.0238392.g002
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In survival analysis, 5-year RFS rate and median survival time (MST) were 28.5% and 17.8
months, respectively. Five-year OS rate and MST were 40.9% and 42.3 months, respectively
(S1 Fig). MST and 1-/5-year OS after initial surgery were 140.6 months and 98.2%/89.2% in
the no-recurrence group, 16.3 months and 61.5%/4.2% in the early recurrence group, and 47.7
months and 98.9%/37.9% in the late recurrence group, respectively (p<0.0001) (Fig 4a). As for
survival after recurrence, simultaneous intra- and extrahepatic recurrence showed the shortest
survival time, compared with extrahepatic-only and intrahepatic-only metastasis: MSTs were
9.4 months for simultaneous intra- and extrahepatic recurrence, 10.7 months for extrahepatic-
Table 2.
Variables Surgical resection (n = 28) Non-Surgical resection (n = 134) BSC (n = 61) P-value
Parameters at initial resection
Sex: Male / Female (%) 16 (57%) / 12 (43%) 82 (61%) / 52 (39%) 40 (66%) / 21 (34%) 0.724
Age � 71 (62–75) 69 (62–75) 72 (64–78) 0.244
BMI � 23.4 (18.7–25) 21.9 (20–24) 22.7 (20.4–24.8) 0.525
Diabetes mellitus (%) 5 (18%) 28 (21%) 8 (17%) 0.794
Tumor factors
CEA (ng/ml) � 2.9 (1.5–4.3) 2.8 (1.7–5.9) 4.6 (2.1–10.1) 0.053
CA19-9 (U/ml) � 18.3 (11–41) 65 (16–439) 146 (21.9–2030) 0.004
Maximum tumor diameter (cm) � 4.9 (3.9–8) 4.8 (3–7.2) 4.8 (3–8.9) 0.582
Morphology
Mass forming / Periductal infiltrating / Intraductal growth
(%)
23 (82%) / 3 (11%) / 2
(7%)
100 (75%) / 33 (25%) / 1 (0.5%) 41 (67%) / 19 (31%) / 1
(1.5%)
0.056
Solitary / Multiple lesion (%) 21 (75%) / 7 (25%) 100 (75%) / 34 (25%) 45 (74%) / 16 (26%) 0.989
Hilar type / Peripheral type (%) 6 (21%) / 22 (79%) 61 (45%) / 73 (54%) 27 (44%) / 34 (56%) 0.058
Treatment factors
Major hepatectomy / Minor hepatectomy (%) 18 (64%) / 10 (36%) 99 (74%) / 35 (26%) 53 (87%) / 8 (13%) 0.04
Lymph node dissection (%) 17 (60%) 101 (75%) 43 (70%) 0.272
Bile duct resection (%) 7 (25%) 47 (35%) 23 (37%) 0.493
Vascular reconstruction (%) 2 (7%) 12 (9%) 7 (11%) 0.776
Adjuvant Chemotherapy (%) 14 (50%) 64 (48%) 15 (24%) 0.006
Pathological factors
Microscopic surgical margin positive (%) 7 (25%) 27 (20%) 11 (18%) 0.748
Lymph node metastasis (%)�� 6 (35%) 43 (41%) 30 (65%) 0.016
Serosa invasion (%) 10 (35%) 62 (46%) 39 (64%) 0.021
Vascular invasion (%) 19 (68%) 102 (76%) 44 (72%) 0.614
fibrosis (%) 6 (21%) 33 (25%) 12 (21%) 0.851
Poorly/undifferentiated (%) 8 (29%) 30 (22%) 16 (26%) 0.716
Parameters at recurrence
Timing of recurrence 0.028
Early Recurrence (� 1-year) 10 (35%) 82 (61%) 39 (64%)
Late Recurrence (>1-year) 18 (64%) 52 (38%) 22 (36%)
Site of recurrence 0.198
Intrahepatic only 14 (50%) 50 (37%) 15 (25%)
Extrahepatic only 11 (39%) 63 (47%) 35 (57%)
Simultaneous Intra- & Extrahepatic 3 (11%) 21 (16%) 11 (18%)
� Median and IQR: interquartile range,
�� Among cases with lymph node dissection.
https://doi.org/10.1371/journal.pone.0238392.t002
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only recurrence, and 18.6 months for intrahepatic-only recurrence, respectively (p = 0.056)
(Fig 4b). Regarding treatment modalities, surgical resection showed longer survival after recur-
rence (MST, 39.5 months) than non-surgical treatment (14.3 months; p<0.0001) or BSC (3.0
months; p<0.0001) (Fig 5a). In sub-group analysis according to recurrence pattern, survival
benefit from surgical resection of the recurrent lesion was not recognized in patients with
simultaneous intra- and extrahepatic metastasis, but was seen in intrahepatic- or extrahepatic-
only metastasis (Fig 5b–5d). Furthermore, in the 223 cases with recurrence, Cox’s proportional
hazard modeling identified early recurrence (HR 1.39, p = 0.046), simultaneous intra- and
extrahepatic metastases compared with intrahepatic-only recurrence (HR 1.65, p = 0.043), and
surgical resection of recurrence compared with BSC (HR 0.06, p<0.001) or non-surgical treat-
ment (HR 0.46, p = 0.007) as independent prognostic factors for post-recurrence survival. In
Fig 3. Correlations between treatment modalities and sites (a) and timing (b) of recurrence.
https://doi.org/10.1371/journal.pone.0238392.g003
Fig 4. Overall survival after primary resection, stratified by recurrence timing (a) and recurrence pattern (b).
https://doi.org/10.1371/journal.pone.0238392.g004
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contrast, among factors at initial surgery, only hilar-type ICC (HR 1.60, p = 0.005) was selected
as a significant factor (Table 3). Regardless of the timing of relapse, the superiority of surgical
resection over other treatment modalities was evident (p<0.0001) (Fig 6a and 6b). Particularly
in late recurrence, surgical resection resulted in long-term survival almost equivalent to that
seen in no-recurrence cases.
Discussion
In this study, 5-year overall RFS and MST were 28.5% and 17.8 months, respectively. In previ-
ous reports focusing on postoperative recurrence of ICC, median RFS has been reported as
11–17 months [5, 19–23]. Similar to those reports, our cohort showed recurrence approxi-
mately 1.5 year after initial surgery. Long-term recurrence and survival outcomes remain dis-
appointing. Risk factors for recurrence after initial surgery are reported to include increased
age, larger tumor diameter, macrovascular invasion, cirrhosis of the underlying liver, lymph
node metastasis, and presence of multifocal disease. These are considered to be risk factors
for both recurrence and poor survival [11–14]. Many reports have mentioned LND for ICC.
The value of routine LND for ICC remains controversial [24–26]. Routine LND can facilitate
Fig 5. Survival curves after recurrence stratified by treatment modalities in all patients with recurrence (a), intrahepatic-only recurrence (b),
extrahepatic-only recurrence (c), and simultaneous intra- and extrahepatic recurrence (d).
https://doi.org/10.1371/journal.pone.0238392.g005
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accurate staging with precise identification of nodal status, and can predict indication for adju-
vant therapy [27]. Given these valuable aspects, LND of regional nodes may be considered as a
standard option [28]. Adjuvant chemotherapy was unable to improve prognosis for all ICC
patients after surgical resection, but could provide a potential survival benefit in subgroups of
patients exhibiting increased risk, such as advanced tumors or positive lymph node metastasis
[29, 30]. In our patient cohort, approximately 70% of patients showed positive nodal status.
Interestingly, the induction rate of adjuvant chemotherapy was higher in the group with
Table 3.
Univariate Analysis Multivariate Analysis
Variables Hazards ratio 95% C.I. P-value Hazards ratio 95% C.I. P-value
Parameters at initial resection
Sex: Male vs Female 1.220 0.927–1.608 0.154
Age 1.021 1.005–1.037 0.010 1.014 0.995–1.033 0.127
BMI 1.012 0.974–1.052 0.520
Diabetes mellitus + vs - 0.859 0.605–1.220 0.396
Tumor factors
CEA (ng/ml) 1.001 0.999–1.002 0.152
CA19-9 (U/ml) 1.000 0.999–1.000 0.120
Maximum tumor diameter (cm) 0.992 0.942–1.043 0.766
Macroscopic type
Mass forming type vs Periductal infiltrating type 0.804 0.577–1.140 0.216
Mass forming type vs Intra-ductal growth type 1.414 0.594–4.616 0.471
Periductal infiltrating type vs Intra-ductal growth type 1.759 0.712–5.846 0.242
Multiple lesions vs Solitary lesion 1.096 0.809–1.485 0.551
Hilar type vs Peripheral type 1.440 1.095–1.895 0.009 1.602 1.154–2.223 0.005
Treatment factors
Major hepatectomy vs Minor hepatectomy 1.183 0.859–1.629 0.300
Lymph node dissection + vs - 0.977 0.723–1.321 0.881
Bile duct resection + vs - 1.241 0.942–1.648 0.122
Vascular reconstruction + vs - 1.043 0.663–1.642 0.853
Adjuvant Chemotherapy vs no-Adjuvant Chemotherapy 0.999 0.761–1.310 0.994
Pathological factors
Microscopic surgical margin positive vs negative 1.103 0.793–1.534 0.558
Lymph node metastasis + vs - 1.363 1.001–1.858 0.048 1.032 0.741–1.437 0.850
Serosa invasion + vs - 1.193 0.913–1.559 0.196
Vascular invasion + vs - 1.129 0.831–1.531 0.435
fibrosis + vs - 1.059 0.771–1.458 0.720
Poorly/undifferentiated vs Well/mod. differentiated 1.001 0.737–1.373 0.970
Parameters at recurrence
Early Recurrence (� 1-year) vs. Late recurrence (>1-year) 1.501 1.145–1.981 0.003 1.398 1.005–1.946 0.046
Recurrence site
Simultaneous intra- & extrahepatic vs. Intrahepatic only 1.719 1.143–2.589 0.009 1.646 1.015–2.671 0.043
Simultaneous intra- & extrahepatic vs. Extrahepatic only 1.278 0.864–1.879 0.220 1.387 0.880–2.184 0.157
Extrahepatic only vs. Intrahepatic only 1.348 1.003–1.813 0.048 1.187 0.835–1.687 0.339
Treatment for recurrence
Surgical resection vs BSC 0.063 0.037–0.110 <0.001 0.059 0.029–0.118 <0.001
Surgical resection vs Non-surgical treatment 0.439 0.287–0.684 <0.0003 0.463 0.264–0.809 0.007
Non-surgical treatment vs BSC 0.145 0.100–0.210 <0.001 0.128 0.082–0.200 <0.001
https://doi.org/10.1371/journal.pone.0238392.t003
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surgical resection than in those with non-surgical treatment or BSC (p = 0.004). Perhaps this
data suggested that adjuvant chemotherapy could increase the resection rate via control of can-
cer spread, leading to oligo-metastasis.
The rate of surgical resection seems to correlate with the timing and type of recurrence.
In other words, this could be affected by the spread of cancer. Preoperative levels of CA19-9
in non-surgical treatment and BSC were thus higher than that with surgical resection. Of
course, taking into account high rates of lymph node metastasis, serosal invasion, and
requirement for major hepatectomy, initial advanced tumor would result in aggressive recur-
rence treated by non-surgical treatment or BSC, instead of surgical resection. In addition,
preoperative CA19-9 could offer a promising predictive biomarker implying subclinical can-
cer spread at initial surgery.
No clear treatment guideline is currently available for recurrence, especially for patients
with localized or systemic intrahepatic ICC recurrence. Several studies have evaluated the
impact of various treatments, such as repeat hepatectomy, radiofrequency ablation, chemo-
therapy or radiotherapy on survival following recurrence of ICC [5, 15, 16, 19–22]. Although
each report has shown the limitation of being a retrospective analysis, surgical resection of the
site of recurrence was clearly established as an effective therapeutic option. In those reports,
median post-recurrence survival after surgical resection was reported as 20–45 months. In this
study, surgical resection of recurrent lesions showed 39.5 months as the MST and 84.6% and
36.3% as the 1- and 5-year OS rates after recurrence, significantly better than those from non-
surgical treatment and BSC. Surgical resection can obviously provide clear survival benefits to
patients with intrahepatic-only or extrahepatic-only recurrence. Conversely, surgical treat-
ment may not be appropriate for simultaneous intra- and extrahepatic recurrence. Compared
with previous reports, our study showed that post-recurrence survival seemed slightly better
after surgical resection. However, these differences would be derived just from patient selec-
tion for surgical resection; in our patient cohort, the indication of surgical resection for recur-
rent ICC was limited to cases with the prospect of R0. Even though surgical resection is the
best treatment modality for recurrent ICC, non-curative repeat surgery could end up provid-
ing outcomes just as dismal as those from non-surgical treatment [23]. This efficacious
Fig 6. Overall survival after primary resection by treatment modality, compared with no-recurrence patients, in early recurrence (�1 year; a) and
late recurrence (>1 year; b).
https://doi.org/10.1371/journal.pone.0238392.g006
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treatment option thus should not be adopted for ‘debulking’ effects, but under a radical “clean-
ing-up” policy for R0.
With regard to tumor localization, hilar type ICC was indicated as one of significant prog-
nostic factors. The pathological background and gross and histological features of ICCs are
reported to differ according to the anatomical site [31, 32]. The hilar type ICCs originated
from intrahepatic large biliary ducts are likely to show aggressive course with metastatic poten-
tial. Though tumor localization could be classified according to radiological findings in this
study, classification based on radiological findings has been reported to accurately reflect his-
tomorphological typing [33, 34]. In fact, hilar type ICC, defined by radiological localization in
this study, showed higher recurrence rate and poorer survival than peripheral type. The low
resection rate for recurrence in primary major hepatectomy cases and hilar type ICCs may be
due to the grade of hilar type ICCs as well as the reduced liver reserve caused by the initial sur-
gery, which may influence the decision to treat patients at the time of recurrence and the post-
recurrent survival.
TTR has been reported as a crucial factor to predict prognosis after recurrence [5]. This
interval is closely associated with tumor biology, including the metastatic potential of intra- or
extrahepatic metastasis. In HCC, optimal cut-off values for differentiating between early and
late tumor recurrence remain controversial [35]. Few studies have explored the issue in ICC,
but TTR� 1 year has been proposed as a valuable cut-off for early recurrence of ICC [18, 36].
According to those reports, we classified two groups to differentiate early and late recurrence.
This cut-off was likely adequate, allowing could clear differentiation of survival both after ini-
tial surgery and after recurrence. Notably, surgical resection of recurrent ICC could show a
positive prognostic impact even for early recurrence. Based on previous reports, surgical inter-
vention for early recurrence showed poorer prognosis than that for late recurrence [5]. On the
other hand, another report found that early recurrence did not affect post-recurrence survival
[22]. Thus, regardless of TTR, surgical resection exerts a positive prognostic effect on survival
after initial surgery or recurrence. However, in early recurrence, only patients with biologically
low-grade recurrences or limited recurrent disease could benefit from surgical resection. In
other words, the power of surgical resection relies heavily on the degree of recurrent-tumor
distribution. Judging whether recurrent tumor represents limited disease is thus essential.
Conclusions
Even if recurrences seem resectable, careful follow-up with chemotherapy may be advisable to
determine biological malignancy. On the other hand, surgical resection for late-phase recur-
rence could provide a curative option offering equivalent prognosis to that of no-recurrence
cases. While surgery remains the only way to obtain radical cure in ICC, surgery alone cannot
achieve cure. Considering treatment strategies for ICC, initial surgery is only the first step and
the introduction of adjuvant chemotherapy based on accurate staging should follow. In cases
with recurrence, the path of surgical resection should always be explored to improve prognosis.
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